Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
|Articles|January 1, 2006
- Volume 0 0
Hydase (hyaluronidase injection, USP)
Advertisement
PrimaPharm Inc (San Diego, Calif) recently received FDA approval for a new drug application for Hydase 150 units/mL for use as a spreading agent to facilitate the dispersion and absorption of other drugs. Hydase is also indicated for hypodermoclysis and as an adjunct in the subcutaneous urography for improving resorption of radiopaque agents. The product is supplied sterile as 150 USP units of hyaluronidase per mL in a 2-mL nonpreserved, single-use glass vial. For more information, call 866-339-6589, or visit
Articles in this issue
almost 21 years ago
Resealable and Nultraviolet Ultraviolet (UV) Inhibitant Bagsalmost 21 years ago
High Alert Insulin Binalmost 21 years ago
Humira (adalimumab)almost 21 years ago
INVANZ (ertapenem for injection)almost 21 years ago
Compounding HOTLINEalmost 21 years ago
Customer Guilty of Prescription Fraud by Supporting Friendalmost 21 years ago
Counterfeit Drugs: A Life-or-Death Problemalmost 21 years ago
Qui Tam Lawsuits Blow the Whistle on PBMsalmost 21 years ago
Can You Read These Rxs?almost 21 years ago
What You Need to Know About Alzheimer's DiseaseAdvertisement
Related to this article
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
The costs to patients, their families, their workplaces, and their communities go well beyond dollars and cents.
Across every setting, the pharmacist's role is to build reliable systems around patients so stroke prevention remains safe and sustainable across the care continuum.
Pharmacists can plan career sabbaticals before retirement with smart savings, employer leave options, and intentional steps that balance their finances with their goals.
Like enzymes and coenzymes, monitoring devices and pharmacists may achieve more together than either can alone.
Every responsibility described in this issue depends on a pharmacy workforce with enough time and support to carry it.
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
2
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
3
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
4
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
5